1stOncology™: Cancer Intelligence Service – Page 8764 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BioEclipse Therapeutics™ to Present at Virtual H.C. Wainwright 23rd Annual Global Healthcare Conference

On September 10, 2021 BioEclipse Therapeutics, a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on its patented natural killer T-cell (NKT)/oncolytic virus technology platform, reported that Pamela Reilly Contag, Ph.D., Founder and CEO, will present at the H.C. Wainwright Annual Global Healthcare Conference taking place virtually September 13-15, 2021 (Press release, BioEclipse Therapeutics, SEP 10, 2021, View Source [SID1234587562]). The prerecorded presentation will be available online starting at 7 a.m. ET on September 13, 2021 and can be accessed via the conference’s virtual platform by registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dr. Contag and members of the BioEclipse management team are also hosting one-on-one meetings with registered investors and biopharmaceutical industry executives.

During her presentation, Dr. Contag will provide an overview of BioEclipse’s business and highlight the company’s proprietary technology platform and the role it plays in the development of a new class of immune therapeutics. These therapies pair the tumor-locating ability of cytokine-induced killer (CIK) cells with the power of an oncolytic virus that selectively infects and kills malignant cells to create a multi-modal therapy that overcomes the limitations that have previously hobbled the efficacy of cellular and oncolytic viral therapies.

Details of the presentation are as follows:

Event:

H.C. Wainwright Annual Global Healthcare Conference

Date:

September 13-15, 2021

Time:

Presentation available online beginning at 7 a.m. ET, September 13, 2021

Registration:

View Source

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

On September 10, 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time.

The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

On September 10, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET (Press release, Y-mAbs Therapeutics, SEP 10, 2021, View Source [SID1234587547]).

This webinar will feature presentations from KOLs Jaume Mora, M.D., Ph.D., SJD Barcelona Children’s Hospital, and Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering. Additionally, Thomas Gad, Chairman, Founder, and President at Y-mAbs, will provide a brief introduction followed by presentations from Steen Lisby, M.D., DMSc, SVP, Chief Scientific Officer at Y-mAbs, and Claus J. Moller San-Pedro, M.D., Ph.D., Chief Executive Officer at Y-mAbs.

Dr. Mora will present frontline data for DANYELZA in High-Risk Neuroblastoma
Dr. Modak will present HITS data for DANYELZA in High-Risk Neuroblastoma
Dr. Lisby will review Y-mAbs’ preclinical and research pipeline including its SADA technology
Dr. Moller will provide a corporate update
Thomas Gad as well as Drs. Modak, Mora, Lisby, and Moller will be available for questions following the presentations.

To register for the event, please click here.

Shakeel Modak, M.D., MRCP is a pediatric hematology-oncology doctor at Memorial Sloan Kettering Cancer Center, Department of Pediatrics in New York. He received his MBBS and M.D. degrees from TN Medical College, Bombay, as well as his MRCP degree from Royal College of Physicians, London. Dr. Modak specializes in the treatment of children and young adults with neuroblastoma and other solid tumors, such as DSRCT. He has been named to Best Doctors, New York City by Castle Connolly for the past six years in a row and in 2014. Dr. Modak has been the principal investigator on more than 12 studies in neuroblastoma and DSRCT. He has also been the co-investigator on over 50 trial protocols.

Jaume Mora, M.D., Ph.D. is the scientific director of the Oncology and Hematology area at SJD Barcelona Children’s Hospital, as well as the director of the Developmental Tumors Laboratory at SJD Barcelona Children’s Hospital. Dr. Mora is a member of several; national and international scientific societies, including the International Pediatric Oncology Society, which has awarded him the Schweisguth Prize, and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO"), which honored him with the young investigator award ("YIA") in 2000, as well as the Career Development Award ("CDA"). In 2011, Dr. Mora was the recipient of the annual BBVA Foundation Award and, in 2006, of the First Prize of the Spanish Association Against Cancer ("AECC") award for the study of childhood cancer.

About DANYELZA (naxitamab-gqgk)

DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor ("GM-CSF"), for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved by the FDA under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.

VBL Therapeutics to Present at Upcoming Conferences

On September 10, 2021 VBL Therapeutics (NASDAQ: VBLT) reported the Company will present in the following upcoming industry conferences (Press release, VBL Therapeutics, SEP 10, 2021, View Source [SID1234587546]):

H.C. Wainwright 23rd Annual Global Investment Conference
Mon., Sept. 13, 2021
Fireside chat available on-demand beginning at 7:00 a.m. ET

Cell & Gene Therapy World Asia 2021 conference
Wed., Sept. 15, 2021
Presentation Time: 4:45 PM (SGT)
Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Change the Treatment Paradigm for Solid Tumors

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Wed., Sept. 22, 2021
Fireside chat at 1:15 PM – 1:55 PM (ET).

Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page.

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

On September 10, 2021 IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, reported financial results and operational highlights for the second quarter ended June 30, 2021 (Filing, 3 mnth, JUN 30, In8bio, 2021, SEP 10, 2021, View Source [SID1234587529]). In addition, the Company provided an overview of recent corporate developments.

"In the second quarter and subsequent months, we have demonstrated progress in both of our clinical programs," said William Ho, Chief Executive Officer and co-founder of IN8bio. "We successfully completed treatment of the first cohort in the INB-200 Phase 1 trial using our genetically modified gamma-delta T cell candidate in development for treating solid tumors. We also completed dosing of the first cohort of the Phase 1 trial of INB-100, an allogeneic gamma-delta T cell product candidate in development for leukemia patients. We anticipate reporting updates to both programs in the coming months, and given our strengthened cash position from the IPO, we will continue to progress our trials and other pipeline programs."

Successful Initial Public Offering

On August 3, 2021, IN8bio completed its initial public offering, in which it issued and sold 4,000,000 shares of common stock at a public offering price of $10.00 per share. The net proceeds to the Company were approximately $32.6 million, after deducting underwriting discounts, commissions and estimated offering expenses. On September 7, 2021, subsequent to the IPO, there were 18,754,553 shares of common stock outstanding.

Second Quarter Business Highlights & Company Updates


During the second quarter, IN8bio presented data demonstrating in vitro activity of INB-300, our DeltEx drug-resistant immunotherapy (DRI) CAR-T cells against glioblastoma multiforme (GBM) at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021. Gamma-delta T cells were engineered with a chlorotoxin CAR-T binding domain and a chemotherapy resistance gene, which enhances binding to tumor cells and survival of concomitant dosing with alkylating chemotherapies, such as temozolomide, or TMZ.

During the second quarter, IN8bio presented data at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from the first cohort of a Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM. INB-200 was generally well tolerated with no observed infusion reactions, cytokine release syndrome (CRS), neurotoxicity or dose limiting toxicities (DLTs). Enrollment for the second cohort of this trial was initiated. All three treated patients exceeded their expected median progression-free survival based on their respective age and O-6-Methylguanine-DNA Methyltransferase (MGMT) status. The Company expects to report additional data from this Phase 1 trial by the end of 2021.

In July 2021, IN8bio appointed Emily Fairbairn and Luba Greenwood as two independent members of the Company’s Board of Directors. Ms. Fairbairn is currently a principal of Transcend Partners and was co-founder and CEO of Ascend Capital. Ms. Greenwood serves as Managing Partner of Binney Street Capital LLC, a venture capital fund established by the Dana Farber Cancer Institute.

In August 2021, IN8bio completed dosing of the first cohort of INB-100, a Phase 1 clinical trial of donor-derived allogeneic gamma-delta T cells in leukemia patients undergoing hematopoietic stem cell transplant (HSCT). No severe adverse infusion reactions or DLTs were observed. The first two patients continue in complete remission more than one year after treatment. The Company expects to report initial results from the first cohort in this Phase 1 trial in 2022, with topline results for all cohorts in 2023.

Second Quarter 2021 Financial Highlights


Cash position: As of June 30, 2021, the Company has cash of $12.0 million, compared to $18.0 million as of December 31, 2020. Subsequent to the end of the second quarter, the Company completed its initial public offering that raised net proceeds of $32.6 million after underwriting discounts, commissions and estimated offering expenses of $7.4 million.

Research and development (R&D) expense: Research and development expense was $2.1 million for the three months ended June 30, 2021, compared to $1.8 million for the comparable prior year period. The increase in R&D expense was due primarily to third-party costs associated with our clinical programs for INB-200 and increased personnel costs, including non-cash stock-based compensation.

General and administrative expense: General and administrative expense was $1.0 million for the three months ended June 30, 2021, compared to $1.1 million for the comparable prior year period. The decrease was due primarily to decreased legal and professional fees partially offset by increased personnel costs, including non-cash stock-based compensation.

Net loss: The Company reported a net loss of $3.1 million and a net loss attributable to common stockholders of $3.8 million, or ($1.00) per basic and diluted common share, for the three months ended June 30, 2021, compared to a net loss of $2.9 million and a net loss attributable to common stockholders of $3.2 million, or ($0.92) per basic and diluted common share, for the comparable prior year period.